;

Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology

SAN FRANCISCO, CA –(CRWENEWSWIRE) -11/18/11 – Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it has entered into a licensing agreement with an undisclosed party for rights to Poniard’s focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK. Under [...]

Posted by admin on January 20th, 2012 | No Comments Posted in Best Stocks To Buy, Chinese Stocks, Top Stocks
;

Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology

SAN FRANCISCO, CA –(CRWENEWSWIRE) -11/18/11 – Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it has entered into a licensing agreement with an undisclosed party for rights to Poniard’s focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK. Under [...]

Posted by admin on December 23rd, 2011 | No Comments Posted in Best Stocks To Buy, Top Stocks To Buy
;

Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology

SAN FRANCISCO, CA –(CRWENEWSWIRE) -11/18/11 – Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it has entered into a licensing agreement with an undisclosed party for rights to Poniard’s focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK. Under [...]

Posted by admin on December 14th, 2011 | No Comments Posted in Best Stocks, Top Stocks To Buy